1
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
4
|
Chan JJ, Flatters D, Rodrigues-Lima F, et
al: Comparative analysis of interactions of RASSF1-10. Adv Biol
Regul. 53:190–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Tommasi S, Dammann R, Jin SG, et al:
RASSF3 and NORE1: identification and cloning of two
human homologues of the putative tumor suppressor gene
RASSF1. Oncogene. 21:2713–2720. 2002. View Article : Google Scholar
|
6
|
Vos MD, Martinez A, Ellis CA, et al: The
pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor
suppressor in the lung. J Biol Chem. 278:21938–21943. 2003.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Chen J, Lui WO, Vos MD, et al: The t(1;3)
breakpoint-spanning genes LSAMP and NORE1 are
involved in clear cell renal cell carcinomas. Cancer Cell.
4:405–413. 2003.PubMed/NCBI
|
8
|
Hesson L, Dallol A, Minna JD, et al:
NORE1A, a homologue of RASSF1A tumour suppressor gene
is inactivated in human cancers. Oncogene. 22:947–954. 2003.
View Article : Google Scholar
|
9
|
Djos A, Martinsson T, Kogner P and Carén
H: The RASSF gene family members RASSF5, RASSF6 and RASSF7 show
frequent DNA methylation in neuroblastoma. Mol Cancer. 11:402012.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Steinmann K, Sandner A, Schagdarsurengin U
and Dammann RH: Frequent promoter hypermethylation of tumor-related
genes in head and neck squamous cell carcinoma. Oncol Rep.
22:1519–1526. 2009.PubMed/NCBI
|
11
|
Meng W, Huebner A, Shabsigh A, et al:
Combined RASSF1A and RASSF2A promoter methylation
analysis as diagnostic biomarker for bladder cancer. Mol Biol Int.
2012:701812012.
|
12
|
Foukakis T, Au AY, Wallin G, et al: The
Ras effector NORE1A is suppressed in follicular thyroid
carcinomas with a PAX8-PPARγ fusion. J Clin Endocrinol
Metab. 91:1143–1149. 2006.
|
13
|
Nakamura N, Carney JA, Jin L, et al:
RASSF1A and NORE1A methylation and
BRAFV600E mutations in thyroid tumors. Lab
Invest. 85:1065–1075. 2005. View Article : Google Scholar
|
14
|
Geli J, Kogner P, Lanner F, et al:
Assessment of NORE1A as a putative tumor suppressor in human
neuroblastoma. Int J Cancer. 123:389–394. 2008.
|
15
|
Hanahan D and Weinberg RA: The hallmarks
of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Vazquez A, Bond EE, Levine AJ and Bond G:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Discov. 7:979–987. 2008. View
Article : Google Scholar : PubMed/NCBI
|
17
|
Richter AM, Pfeifer GP and Dammann RH: The
RASSF proteins in cancer; from epigenetic silencing to functional
characterization. Biochim Biophys Acta. 1796:114–128.
2009.PubMed/NCBI
|
18
|
Macheiner D, Heller G, Kappel S, et al:
NORE1B, a candidate tumor suppressor, is epigenetically silenced in
human hepatocellular carcinoma. J Hepatol. 45:81–89. 2006.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Calvisi DF, Evert M and Dombrowski F:
Pathogenetic and prognostic significance of inactivation of RASSF
proteins in human hepatocellular carcinoma. Mol Biol Int.
2012:8498742012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Shinmura K, Tao H, Nagura K, et al:
Suppression of hydroxyurea-induced centrosome amplification by
NORE1A and down-regulation of NORE1A mRNA expression in non-small
cell lung carcinoma. Lung Cancer. 71:19–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Fernandes MS, Carneiro F, Oliveira C and
Seruca R: Colorectal cancer and RASSF family - a special emphasis
on RASSF1A. Int J Cancer. 132:251–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Macheiner D, Gauglhofer C, Rodgarkia-Dara
C, et al: NORE1B is a putative tumor suppressor in
hepatocarcinogenesis and may act via RASSF1A. Cancer Res.
69:235–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Geli J, Kiss N, Lanner F, et al: The Ras
effectors NORE1A and RASSF1A are frequently
inactivated in pheochromocytoma and abdominal paraganglioma. Endocr
Relat Cancer. 14:125–134. 2007.
|
24
|
Lee CK, Lee JH, Lee MG, et al: Epigenetic
inactivation of the NORE1 gene correlates with malignant
progression of colorectal tumors. BMC Cancer. 10:5772010.PubMed/NCBI
|
25
|
Guo C, Tommasi S, Liu L, et al: RASSF1A is
part of a complex similar to the Drosophila
Hippo/Salvador/Latstumor-suppressor network. Curr Biol. 17:700–705.
2007. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zeng Q and Hong W: The emerging role of
the hippo pathway in cell contact inhibition, organ size control,
and cancer development in mammals. Cancer Cell. 13:188–192. 2008.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Chan SW, Lim CJ, Chen L, et al: The Hippo
pathway in biological control and cancer development. J Cell
Physiol. 226:928–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Avruch J, Praskova M, Ortiz-Vega S, et al:
Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2
kinases. Methods Enzymol. 407:290–310. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ehrkamp A, Herrmann C, Stoll R and Heumann
R: Ras and rheb signaling in survival and cell death. Cancers.
5:639–661. 2013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Ng YK, Lau WS, Lui VW, et al: Full-length
Mst1 exhibits growth promoting function in human hepatocellular
carcinoma cells. FEBS Lett. 587:496–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Aoyama Y, Avruch J and Zhang XF: Nore1
inhibits tumor cell growth independent of Ras or the MST1/2
kinases. Oncogene. 23:3426–3433. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Naryzhny SN: Proliferating cell nuclear
antigen: a proteomics view. Cell Mol Life Sci. 65:3789–3808. 2008.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Brinckerhoff CE, Rutter JL and Benbow U:
Interstitial collagenases as markers of tumor progression. Clin
Cancer Res. 6:4823–4830. 2000.PubMed/NCBI
|
34
|
Trieb K and Kotz R: Proteins expressed in
osteosarcoma and serum levels as prognostic factors. Int J Biochem
Cell Biol. 33:11–17. 2001. View Article : Google Scholar : PubMed/NCBI
|
35
|
Grigorian M and Lukanidin E: Activator of
metastasis in cancer cells, Mst1/S100A4 protein binds to tumor
suppressor protein p53. Genetika. 39:900–908. 2003.(In
Russian).
|